Subject: Bonus-No.138243079188 - Please-Claim Your $50-Walgreens Reward-Now.

From: WalgreensBonus <[email-masked]>
Date: Thu, 23 Feb 2017 11:21:58 -0700

Hello [email-masked],

We wanted to reach out to let you know that you have earned-yourself $50-in Walgreens-Points!

These bonus-points will be expiring-by the end of this week if you do not claim-them however, so please go below here and take a short-survey about your shopping-experience at Walgreens to claim your-reward right now.

Go Here Now to Redeem-Your Walgreens-Bonus

Go here.now if you are-looking to.quit these-rewardads.

_-2885 Sanford.Ave.

:-SouthWest_No.40442-Grandville, M.I. #49418.

Walgreens Boots Alliance Inc. expects its planned $9.4 billion purchase of Rite Aid Corp. to close early next year, even as talks with regulators over which drugstores should be divested have taken longer than anticipated. The shares rose as much as 4.5 percent, the biggest intraday gain in four months, after Walgreens Chief Executive Officer Stefano Pessina told analysts on a conference call that the transaction is moving through regulatory review. “As far as we can see today, we are absolutely confident that we can do the deal,” he said. Earlier on Thursday, Walgreens postponed the end date of the Rite Aid agreement from Oct. 27 to Jan. 27, saying it expects the transaction to be completed in early 2017. The purchase could boost the number of U.S. pharmacies it owns to 12,000 or more from 8,200, depending on how many stores are divested. The company also reported fiscal fourth-quarter profit that topped analysts’ estimates, as cost cutting and solid prescr
iption growth made up for weak front-of-store retail sales in the U.S., its biggest market. The shares were up 3 percent to $79.52 at 11:02 a.m. in New York. The slight delay in the Rite Aid deal closing time frame is a good sign, because it suggests that the companies are sorting out which stores to divest with the regulators, according to Ross Muken, an analyst at Evercore ISI who recommends buying the shares. It means regulators aren’t outright blocking the deal. “The longer the process takes the more likely it is to close,” he said in a note to clients. Earnings, excluding some items, were $1.07 a share in the quarter ended Aug. 31, the drugstore chain said in a statement, topping the 99-cent average of predictions compiled by Bloomberg. But revenue fell short of predictions. U.S. same-store retail sales, which exclude newest locations, declined 0.3 percent. In spite of renovations of its stores’ cosmetics areas to bring in more shoppers, especially healt
h-conscious women, the Deerfield, Illinois-based company has so far failed to boost sales of front-of-store products. Same-store retail sales in the U.S. have declined in three out of the past four quarters.

Previous articles touched on the concept of inventorying your wealth by storing it in high-quality blue-chip stocks. A large portion of this strategy is systematic stock purchases on a monthly basis, but we also are always looking for strategic opportunities to deploy cash. If a little investing history serves any basis, an opportunity may present itself in Walgreens-Boots Alliance (NASDAQ:WBA) soon. Walgreens at a Glance On paper, Walgreens is a great candidate to store wealth in for the long term. They have paid dividends since 1933 and have been raising them annually since 1976. Earnings are also increasing by merit of their recent acquisition of Boots Alliance, and look to further increase their earnings base with an acquisition of Rite Aid later this year. 12,755 stores located globally are operated under the brand's umbrella, which means there are 12,755 sources of earnings sending in cash annually. Nearly $90 billion is generated from these stores, $81 billion of which
comes from the United States. The wholesale pharmaceutical division kicks in another $15 billion in revenue, and $376 million in operating income. The company is a powerhouse, and it is hard to dent the earnings in a significant manner given the geographic dispersion of the company's pharmacies. With the above said, one of the greatest risks to Walgreens in my opinion would be reputational. As noted, the company has nearly 13,000 stores, and hundreds of stores would have to struggle in order to significantly affect the company's earnings. There is a risk of new stores cannibalizing existing store sales, but acquiring Rite Aid will allow them to close more competing locations and allow them to close other underperforming stores. With a low risk of having too concentrated a footprint, any other risk will revolve around incidents that could keep customers en masse from coming to their stores. Chipotle experienced an event like this earlier this year when they dealt with outbreaks of E
-coli and Norovirus caused by their food. Walgreens does not prepare food, but selling a faulty product that causes harm to customers could keep people away. Today, the specter of one such reputational risk raised its head. Blood Tests and Salad Oil First off, a little investing history is due. Controversy can be a great way to lower the valuation of a stock and can create opportune price points for initiating a position. Warren Buffett is famous for the risk he took on American Express (NYSE:AXP) back in the 1960's after they had been suckered by non-existent salad oil as collateral for a loan. The stock fell by 50% but the underlying business performance was still in place, which created a massive buying opportunity in a quality stock. Buffett did not hold that investment for forever, but it was his one of his first big investing achievements. Today, a similar opportunity may come at Walgreens due to forthcoming troubles with their partnership at Theranos.